14 - 16 May, 2019 | Hotel Novotel Amsterdam Schiphol Airport, Amsterdam, Netherlands

Conference Day One

9:20 am - 9:50 am Opening Keynote: A Global View of the Biosimilars Market

Dr Paul Cornes - Oncologist, NHS
  •  Discuss the regionally variable challenges and opportunities that exist across the global biosimilars market  
  • Consider recent and historical trends with a view to explore the future of biosimilars on a global scale
  • Join your colleagues in an open forum for discussion on how you can help drive the industry for mutual benefit
img

Dr Paul Cornes

Oncologist
NHS

9:50 am - 10:25 am An Update on the Current Legal Landscape for Biosimilars in the US

Paul Calvo - Director Sterne, Kessler, Goldstein & Fox
  • Deep-dive into the latest updates on biosimilars litigation
  • Explore antitrust and unfair competition issues in biosimilar markets
  • Discuss the effects of anti-substitution legislation at the state level on biosimilar uptake

img

Paul Calvo

Director
Sterne, Kessler, Goldstein & Fox

10:25 am - 11:10 am Panel Discussion: Exploring the Sensitivity and Complexity of the North American Biosimilars Market

Michael Muenzberg - Biosimilars Consultant Biosimilars Consulting CH
Dr Paul Cornes - Oncologist, NHS
Don Stewart - Chief Executive Officer, PlantForm

  • Overcome the current battle to combat misinformation surrounding biosimilars in the US, and the essential methods to boost stakeholder confidence, in the face of immense competition from biologics
  • Discuss the current regulatory landscape with respect to the FDA Biosimilar Action Plan and the newly published regulatory framework  regarding  the use of  real world evidence and real world data
  • Explore the game-changing concept of the ‘Purple Book’ for pharmacists, asking “Does this make either medical or commercial logic?”

img

Michael Muenzberg

Biosimilars Consultant
Biosimilars Consulting CH

img

Dr Paul Cornes

Oncologist
NHS

img

Don Stewart

Chief Executive Officer
PlantForm

11:10 am - 11:40 am Networking Coffee Break

11:40 am - 12:15 pm Case Study: Cracking the Canadian Market and Breaking into Brazil

Don Stewart - Chief Executive Officer, PlantForm

  • Explore the novel and low cost method of using plants in the development and manufacture of biosimilars
  • Discover how PlantForm was able to maximise success in the conservative Canadian market and break into Brazil
  • Looking to the future: prospects for PlantForm in China, India and South Africa, considering regulatory differences and market access strategy
img

Don Stewart

Chief Executive Officer
PlantForm

12:15 pm - 12:50 pm Mexico and the Wider South American Market

Jose Carlos Ferreyra - President, Mexican Pharmaceutical Institute
  • Discover how to navigate one of the largest and complex public health services in the world, with key takeaways to target your approach to world-wide payers
  • Explore the access roadmap to 150 government public buyers, with a comprehensive study of timings and procedures
  • Discuss the impact of biosimilars in emerging markets with example case-studies from Mexico, considering both market value and patient access
  • Draw comparisons with principle countries of the LATAM region 
img

Jose Carlos Ferreyra

President
Mexican Pharmaceutical Institute

12:50 pm - 1:50 pm Networking Lunch

1:50 pm - 2:25 pm Case Study: Discovering the Opportunities in the Chinese Market Place and Bridging the Gap to New Pharmerging Markets

Fabiola Santillan - Country Manager, TTY Biopharm
  • Consider the low penetration of biologic medicines and what this means for the prospective biosimilar market, in respect to unmet medical needs 
  • Volumes Game: Question why the Chinese market does not have the same fears for sustainability as other global market places
  • Case Study: Moving between the Chinese, Taiwanese and Mexican market places 

img

Fabiola Santillan

Country Manager
TTY Biopharm

2:25 pm - 2:55 pm Case Study: Launching a Biosimilar into the European Marketplace in 2019

Anna Aillerie - Head Of Commercial Operations, Biotechnology Business Unit, Gedeon Richter
  • Explore the current European market place by analysing the successes and failures of Big Pharma and SMEs  in their approach to  biosimilar commercialisation 
  • Benchmark your branding practice and commercial strategy against the challenges and opportunities encountered in the preparation for launch of a new biosimilar 
  • Get a sneak peek into pre-marketing and marketing activities around a launch of a new biosimilar into the European market  

img

Anna Aillerie

Head Of Commercial Operations, Biotechnology Business Unit
Gedeon Richter

2:55 pm - 3:25 pm Networking Coffee Break

3:25 pm - 4:00 pm Miracle Market? A Discussion of the Danish Market Place

Peter Jørgensen - Director, Industrial Association for Generic and Biosimilar Medicines
  • Explore the successful market penetration of biosimilars into Denmark, with consideration of the tendering system, high uptake and low prices 
  • Uncover what role the patients, health authorities and physicians had in the biosimilar uptake
  • The future of the Danish market place: a discussion on sustainability and lessons learned 
img

Peter Jørgensen

Director
Industrial Association for Generic and Biosimilar Medicines

4:00 pm - 4:35 pm The Four Pillars Supporting Biosimilar Uptake in Spain

Julián Sanz - Iberia Market Access Manager Lead (Spain & Portugal), Santen Pharmaceutical
  • Discover the nuances of the Spanish biosimilar market and the barriers that have historically limited uptake 
  • Explore how Biogen have built up opportunities in the Spanish market and resolved difficulties  
  • Develop and execute a clear strategy to overcome the challenges associated with payers, prescribers and price in Spain 
img

Julián Sanz

Iberia Market Access Manager Lead (Spain & Portugal)
Santen Pharmaceutical

4:35 pm - 5:05 pm Networking Coffee Break

  • Explore the need for collaboration between Payers, Regulators and Industry to enhance patient access to biosimilars in Europe
  • Consider how policy can be utilized as a tool to broaden patient access
  • What does the future hold for the stability of the Biosimilars Market in the EU?
img

Lincoln Tsang

Partner
Arnold & Porter Kaye Scholer LLP

img

Anna Aillerie

Head Of Commercial Operations, Biotechnology Business Unit
Gedeon Richter

img

Simon Keady

EU Market Access Lead - Biosimilars
Biogen

5:45 pm - 6:15 pm Round Table Discusions

  1. Europe – Work collaboratively with your peers tackle the European market 
  2. North America – Overcome the stringent regulations of Canada and intense competition in the US by  bringing your challenges to the forefront of the industry  
  3. LATAM –  Explore new opportunities in the LATAM region 
  4. Asia – consider the varied markets of China, Korea, Japan and India